Obama: So, Dr. Harats, can you tell me more about this merger with Notable Labs Inc.?

Harats: Of course, Mr. Obama. This merger will position our new enterprise to deliver both near and long-term value for shareholders of both companies and patients.

Obama: I see. And can I ask, what specifically does this mean for VBL’s pipeline and development of new drugs?

Harats: The successful closing of the sale of VBL’s manufacturing facility for $7.1 million has provided an influx of non-dilutive capital that can be employed by the combined entity to advance its pipeline. Notable has applied its proprietary Predictive Precision Medicines Platform (PPMP) to selecting and developing two clinical-stage therapeutic candidates in acute myeloid leukemia (AML); Phase 2a results for lead asset Volasertib in adult AML in platform-predicted responding patients are expected in 3Q 2024.

Obama: Hmm, that all sounds very interesting. But can you explain why VBL reported a net loss of $32.3 million in 2022?

Harats: Well, that’s just a reflection of our investment in research and development. We believe that investing in cutting-edge therapies is key to our long-term success.

Obama: I understand the need for investment in R&D, but I couldn’t help but notice that you didn’t mention anything in your report about the recent FDA warning letter regarding VBL’s clinical trial conduct.

Harats: [pauses] The FDA letter was related to a single site in our trial, and we have already taken corrective measures to address the issue. We remain committed to conducting safe and effective clinical trials.

Obama: Alright, thank you for addressing that. And one last thing, can you comment on the recent allegations made by a well-known short seller that VBL is deceiving investors about the true status of its clinical trials?

Harats: [pauses] I categorically deny those allegations. VBL is committed to transparency and accuracy in all of our communications with investors and stakeholders.

Original Release: https://www.globenewswire.com/news-release/2023/03/14/2626587/0/en/VBL-Therapeutics-Reports-Full-Year-2022-Financial-Results-and-Provides-Corporate-Update.html

Previous Post
CEO of Prenetics Admits to Lying About Financial Data, Blames Katherine Hepburn’s Ad for His Epiphany.
Next Post
MeiraGTx CEO Admits to Lying in SEC Disclosure, Exposes Company to Legal Consequences